Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
2000 Turkeys
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
2000 Turkeys
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
28.45
-0.41 (-1.44%)
Delayed Quote
Updated: 3:36 PM EST, Nov 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Pfizer
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue
↗
Today 13:50 EST
J&J's quarterly sales have climbed with few setbacks, while Pfizer's have swung between $13.7 billion and $17.8 billion over eight quarters.
Via
The Motley Fool
Pfizer CEO Sees Growth Beyond Patent Cliff, Highlights Monthly Obesity Drug Ambitions
↗
Today 6:12 EST
Pfizer (NYSE:PFE) expects recently launched medicines and a growing pipeline to help it emerge from a period of patent expirations with high single-digit growth, CEO Albert Bourla said at the Jefferies...
Via
MarketBeat
Topics
Intellectual Property
Today's Most-Active S&P 500 Stocks: Ford Leads Volume as SMCI and Micron Fall
↗
November 16, 2026
Via
Chartmill
Topics
Stocks
2 Stocks With Dividend Yields of 4% or More to Buy in November
↗
November 16, 2026
These two stocks can provide reliable income for your portfolio for years to come.
Via
The Motley Fool
Topics
Artificial Intelligence
5 Dividend Stocks With High Yields That Are Safer Than You Might Think
↗
November 14, 2026
A high yield is a sign that investors are worried about a business, but sometimes that concern is overwrought.
Via
The Motley Fool
Topics
Intellectual Property
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?
↗
November 14, 2026
Novo Nordisk's obesity-drug dominance faces rising rivals, while Pfizer's cheaper valuation and cash flow tell a different story for income-minded investors.
Via
The Motley Fool
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
↗
November 14, 2026
Axsome's revenue has climbed about 54% while Moderna's net losses run deep, but a steep valuation gap may tip the scales for patient investors.
Via
The Motley Fool
Topics
Intellectual Property
Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?
↗
November 14, 2026
These healthcare dividend stocks appeal to investors in different ways.
Via
The Motley Fool
Topics
Earnings
Intellectual Property
Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion. Is the High-Yield Stock a Buy Right Now?
↗
November 13, 2026
Pfizer isn't out of the woods yet, but it is proving it remains a well-run drugmaker.
Via
The Motley Fool
Topics
Intellectual Property
2 Bargain Stocks to Buy With $1,000 in November
↗
November 13, 2026
Stocks are finally settling down following a few weeks of extreme volatility. Use this lull as an entry point before more investors realize many of these names are currently on sale at a great price.
Via
The Motley Fool
Topics
Intellectual Property
Exelixis Has 2 Major Catalysts Coming by March 2027. Here's What Investors Should Watch.
↗
November 13, 2026
These catalysts could impact growth down the road.
Via
The Motley Fool
Most Active S&P 500 Stocks: KDP, Ford, AT&T Lead Today's Session
↗
November 12, 2026
Via
Chartmill
Topics
Stocks
3 Magnificent Dividend Stocks Yielding 4% or More to Buy in November
↗
November 10, 2026
These three blue chip dividend stocks offer higher yields while standing out in terms of dividend coverage and growth.
Via
The Motley Fool
Topics
Intellectual Property
Worried About a Market Crash? These 3 High-Yielding Stocks Can Be Safe Long-Term Options
↗
November 10, 2026
These stocks pay as much as 5.9% in dividends.
Via
The Motley Fool
Topics
Economy
S&P 500 Most Active Stocks in Today's Session: SMCI, AT&T, Ford Lead Volume
↗
November 10, 2026
Via
Chartmill
Topics
Stocks
Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the Stock
↗
November 10, 2026
This surprising healthcare stock has been outperforming the markets this year.
Via
The Motley Fool
Topics
Intellectual Property
Medicus Pharma (MDCX) Q3 2026 Earnings Call Transcript
↗
November 09, 2026
A SkinJect SPAC plan and melanoma focus mark the next phase.
Via
The Motley Fool
Topics
Earnings
Most-Active S&P 500 Stocks in Today's Session
↗
November 09, 2026
Via
Chartmill
Topics
Stocks
Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028
↗
November 09, 2026
Investors shouldn't count out Pfizer in the GLP-1 market just yet.
Via
The Motley Fool
Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials
↗
November 07, 2026
Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too.
Via
The Motley Fool
After the Midterm Rally, the Dow Is on Track to Beat the Nasdaq for the First Time Since 2022. Here's What History Says Could Come Next.
↗
November 06, 2026
The Dow tends to outperform the Nasdaq during growth stock-driven sell-offs.
Via
The Motley Fool
Topics
Artificial Intelligence
Stocks
S&P 500 Most-Active Stocks Today: Oracle Leads Volume, Microchip Drops 11.56%
↗
November 06, 2026
Via
Chartmill
Topics
Stocks
3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market
↗
November 06, 2026
They are so much more than just dividend stocks.
Via
The Motley Fool
Topics
Intellectual Property
NVAX Q3 2026 deep dive: Sanofi milestone and cost controls shape outlook
November 06, 2026
Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported revenue ahead of Wall Street’s expectations in Q3 2026, but sales fell by 3% year on year to $68...
Via
StockStory
3 value stocks we think twice about
November 05, 2026
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
Via
StockStory
Halozyme Therapeutics (NASDAQ:HALO) surprises with Q3 2026 sales but stock drops
November 05, 2026
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) announced better-than-expected revenue in Q3 2026, with revenue up 39.2% year on ...
Via
StockStory
Most Active S&P 500 Stocks: Marvell, Oracle, Ford Lead Nov. 5 Trading
↗
November 05, 2026
Via
Chartmill
Topics
Stocks
Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?
↗
November 05, 2026
Amgen's growth engine and Pfizer's value appeal pull in opposite directions, and the valuation gap between them is wider than many expect.
Via
The Motley Fool
Topics
Intellectual Property
Most-Active S&P 500 Stocks for Nov. 4, 2026
↗
November 04, 2026
Via
Chartmill
Topics
Stocks
Pfizer: 3 Key Takeaways for Long-Term Investors
↗
November 04, 2026
The patent-expiry question is still open: whether cutting costs now buys enough time for late-stage trials to replace fading blockbuster revenue.
Via
The Motley Fool
Topics
Earnings
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today